loader2
Partner With Us NRI

Indegene Ltd share Price Today

Company details

544.00
558.85
470.10
660.00
6M Return 0.00%
1Y Return -2.57%
Mkt Cap.(Cr) 13,308.14
Volume 923,665
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 923,665

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Consulting Services company Indegene announced FY24 results:

  • FY24 Revenue up by 12.3% YoY, crosses Rs 2,500 crore
  • FY24 EBITDA up 28.6%, and PAT up by 26.5% Yoy
  • FY24 EBITDA% up by 286 bps, and PAT% up by 146 bps YoY 

Manish Gupta, Chairman and Chief Executive Officer - "We are pleased with our continued performance this quarter and the full year. Today in the marketplace we are known as a digital first commercialization partner to the global life sciences industry. We have 63 active clients and work with all the top 20 global pharmaceutical companies. Our revenues very closely mirrors the global life sciences industry's spends on operations. 69% of our revenues come from the top 20 Pharma companies. Global Life Sciences industry is more than USD 1.8 Tn Industry. We are excited about the opportunity in front of us." 

Suhas Prabhu, Chief Financial Officer - "Our financial results reflect our focus on operational excellence, cost optimization and value-driven service delivery. While revenue grew steadily, we delivered strong growth in margins, with a healthy cash conversion and a strong balance sheet, providing us with the flexibility to invest in growth opportunities. We remain committed to delivering value to our clients and shareholders through deep domain expertise, innovation and operational excellence."

Result PDF

View Other Company Results

Indegene Ltd shares SWOT Analysis

Strengths (3)

  • Rising Net Cash Flow and Cash from Operating activity
  • Company with Low Debt
  • Annual Net Profits improving for last 2 years

Weakness (0)

Data not found

Opportunity (0)

Data not found

Threats (0)

Data not found

Resistance and support

R1 562.0
R2 567.9
R3 576.9
Pivot

553.02

S1 547.2
S2 538.2
S3 532.3
EMA SMA
560.0
-
-
-
556.3
-
-
-
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Purchase 2024-05-13 580.4 1387957 NSE
GRT STRATEGIC VENTURES LLP Bulk Purchase 2024-05-13 580.96 1358739 NSE
NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 2024-05-13 580.8 1387957 NSE
Name Category Shares
Anand Kiran PUBLIC 2.18%
Trusts PUBLIC 2.88%
Aarabhi Partners Consultants Llp PUBLIC 2.11%
LLP PUBLIC 2.11%
Chestnut Associates (Ptc) Limited As Trustee Of N Foundation PUBLIC 1.44%
Sycamore Philanthropy (Ptc) As Trustee Of Aalamaram Foundation PUBLIC 1.44%
Vida Trustees Private Limited (Trustee of Fig Tree Trust) in capacity as partner of Group Life Spr PUBLIC 2.34%
Gaurav Kapoor PUBLIC 2.62%
Manish Gupta PUBLIC 8.97%
Rajesh Bhaskaran Nair PUBLIC 7.13%
Sanjay S Parikh PUBLIC 5.01%
Nadathur Fareast Pte Ltd PUBLIC 22.03%
Ca Dawn Investments PUBLIC 14.52%
Bpc Genesis Fund I Spv Ltd PUBLIC 6.29%
Bpc Genesis Fund I A Spv Ltd PUBLIC 3.26%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Indegene Ltd Stocks COMPARISON

Financials( in Cr) Indegene Ltd Central Depository Services (India) Ltd TBO Tek Ltd Godrej Agrovet Ltd RattanIndia Enterprises Ltd
Price 556.20 2,387.25 1,902.90 675.30 84.41
% Change 1.01 18.99 0.17 1.35 4.87
Mcap Cr 13,308.14 24,946.76 20,663.21 12,980.01 11,667.74
Revenue TTM Cr 2,306.13 555.09 1,064.59 9,373.68 4,123.79
Net Profit TTM Cr 266.10 275.96 148.49 295.36 -286.10
PE TTM 39.73 59.52 99.13 36.12 24.72
1 Year Return -2.57 113.67 35.31 49.40 101.46
ROCE 29.51 31.39 51.92 10.56 0.89
ROE 29.12 23.93 51.90 10.47 0.82
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,063.73 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,542.69 26,564.54
LAST 3M 107,300.08 -872.81
LAST 6M 187,950.75 839.71
LAST 12M 304,454.24 86,051.23
Indegene Limited - Trading Window

Jun 28, 2024 l NSE Announcement

Indegene Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 25, 2024 l NSE Announcement

Indegene Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 24, 2024 l NSE Announcement

Date Action Type Ratio
No data found

Indegene Ltd Information

Stock PE (TTM)
39.73
Promoter Holding
0%
Book Value
91.532
ROCE
29.51%
ROE
29.12%
Description
  • Indegene Ltd was incorporated as `Indegene Lifesystems Private Limited` at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to `Indegene Private Limited` and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to `Indegene Limited` and a fresh certificate of incorporation was issued to Company by RoC, on November 17, 2022. The Company is a "digital-first" commercialization company focused exclusively on the global life sciences industry. Their solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. Their portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a "digital first" approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients. Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals. In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited. On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021. The Company acquired Cult Health, a full-service healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022. The Company is planning to raise capital from Public by raising Rs 950 crores through fresh issue and 36,291,497 Equity Shares through Offer For Sale.

Registered Address

Aspen Block G4 3rd Flr Manyata, Embassy Busi. Park Nagawara, Bengaluru, Karnataka, 560045

Tel : 91-80-4674 4567/+91-80-4644 7777
Email : compliance.officer:indegene.com
Website : http://www.indegene.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) :
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 544172
NSE Code : INDGN
Book Closure Date (Month) :
BSE Group : B
ISIN : INE065X01017

FAQ’s on Indegene Ltd Shares

You can buy Indegene Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Indegene Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 28, 2024 03:57 PM the closing price of Indegene Ltd was Rs.556.20.

The latest PE ratio of Indegene Ltd as of Jun 28, 2024 03:57 PM is 39.73

The latest PB ratio of Indegene Ltd as of Jun 28, 2024 03:57 PM is 0.16

The 52-week high of Indegene Ltd share price is Rs. 660.00 while the 52-week low is Rs. 470.10

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 28, 2024 03:57 PM, the market cap of Indegene Ltd stood at Rs. 13,308.14 Cr.

Download App

Download Our App

Play Store App Store
market app